Monday, March 27, 2023 | Back issues
Courthouse News Service Courthouse News Service

Pharma Class Action

SAN FRANCISCO - Shareholders claim Clovis Oncology goosed its share price with false and misleading reports about its rociletinib drug, and shares fell from $69.19 to $30.24 on Nov. 16 when the truth came out, in Federal Court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.